SGLT2 Inhibitors in the Modern Era: Why and Where?

Slides:



Advertisements
Similar presentations
What's New in Basal Insulin for Diabetes
Advertisements

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.
Short-, Intermediate-, Long-Acting Insulins
Diabetic Dyslipidemia in Practice
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
Special Consideration in Insulin Therapy
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
SGLT2 Inhibitors and Their Clinical Impact:
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
What Comes Second?.
Updates on Outcomes for Novel T2D Therapies
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
Statins and the Elderly Patient
Resistant Hypertension
Diabetes mellitus SGLT2 inhibitors: Novel concepts (cont’d):
Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Tailoring Hemophilia Prophylaxis Therapy
An Update on PCSK9 Inhibitors
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
HCV Protease Inhibitors in Clinical Practice
Implementing Best Practices in the Management of Allergic Diseases
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Tackling CV Risk in T2DM.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Early and Intensive T2D Management:
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Breaking Down the CVOTs
Novel Approaches in T1D Management
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
The Primary Care Guide to New CGM Devices and the AGP
Antihyperglycemic Therapy
Modern Advances in Glucose Monitoring
Understanding and Addressing the Needs of Patients With AD
The Role of the Kidney in Glucose Control
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Managing Age-Related Clinical Issues in Hemophilia
Dual SGLT1/SGLT2 Inhibition in T1D
Hypoglycemia: The Most Common Barrier to Effective Diabetes Management
A Guideline-Based Approach to HCV Care
HCV Protease Inhibitors in Clinical Practice
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Add-On Therapy to Insulin in T1DM Management
Addressing Treatment Challenges in Cystic Fibrosis
Patient Selection for Modern T2D Agents
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Improving Effective Basal Insulin Use in Clinical Practice
What Does the Future Hold and What Will It Mean for Patients?
Improving Adherence to Antiplatelet Therapy After an ACS Event
Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators
Assessing the Burden of Hyperkalemia
Lipid Updates From Spring 2019
Assessing the Burden of Hyperkalemia
Championing Evidence-Based Care in Patients With Acute Low Back Pain
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
What's New in Oral Combination Therapy for Type 2 Diabetes?
Emerging Advances in Reducing Renal Complications of T2D
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Top Tips in Evidence-Based Care for HFrEF
RAASi Enabling in the Modern Era
PCSK9 Inhibitors and Real-World Evidence
Presentation transcript:

SGLT2 Inhibitors in the Modern Era: Why and Where?

Goals

The Kidney and Glucose Homeostasis

Cellular Glucose Homeostasis

SGLT2 Therapy: Clinical Benefits

SGLT2 Therapy: Clinical Benefits

SGLT2 Therapy: Hypoglycemia

SGLT2 Therapy: Genital Infection

SGLT2 Therapy: Blood Pressure

SGLT2 Therapy: Benefits

SGLT2 Therapy: in Clinical Use

SGLT2 Therapy: Long-term Impact

SGLT2 Therapy: Typical Patient

SGLT2 Therapy: ADA Guidelines

2013 AACE T2D Treatment Guidelines

SGLT2 Therapy: Contraindications and Caution

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)